Scientists hope to begin clinical tests of a new drug that they say has had “positive results” in laboratory tests against Covid-19.
It follows laboratory-based studies by the University of St Andrews spin-out company, Pneumagen, into preventing coronavirus infections.
These studies included the Sars-CoV-2 infection, which is the cause of Covid-19.
The successful studies involved both treating and blocking infection.
The Pneumagen team used the anti-viral drug Neumifil and Carbohydrate Binding Modules (mCBMs) to block the Sars-CoV-2 virus from getting into lung cells.
Working with Public Health England and, separately, the University of Glasgow’s Centre for Virus Research, Pneumagen tested its mCBMs against coronaviruses using plaque reduction tests.
The mCBMs were found to reduce the number of Sars-CoV-2 plaques – visible structures in a sheet of cells – when they